Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Sameer Z. Ahmed

Hematology Oncology | Hematology | Oncology
Franciscan Physician Network
1701 S Creasy Ln, 1w93, 
Lafayette, IN 
Accepting New Patients
Offers Telehealth
Advanced in WT1-Related Wilms Tumor Syndromes
Franciscan Physician Network
1701 S Creasy Ln, 1w93, 
Lafayette, IN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sameer Ahmed is a Hematologist Oncology specialist and a Hematologist in Lafayette, Indiana. Dr. Ahmed is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, Childhood Iron Deficiency Anemia, Lung Cancer, and Bone Marrow Aspiration. Dr. Ahmed is currently accepting new patients.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IN
Hospital Affiliations
Monroe Hospital
Putnam County Hospital
Franciscan Health Mooresville
Franciscan Health Indianapolis
Languages Spoken
English
Armenian
Mandarin
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health Plan
  • INSURANCE PLAN
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

FRANCISCAN PHYSICIAN NETWORK
1701 S Creasy Ln, 1w93, Lafayette, IN 47905

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Drug
Study Drug: Sotorasib
Study Phase: Phase 2
A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)
A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug
Study Drugs: Avelumab, Talazoparib, Talazoparib Tosylate
Study Phase: Phase 2
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug, Biological
Study Drugs: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab
Study Phase: Phase 2
A Prospective, Multicenter Atherectomy Study Showing Luminal Gain in Subjects With Peripheral Vascular Blockages
A Prospective, Multicenter Atherectomy Study Showing Luminal Gain in Subjects With Peripheral Vascular Blockages
Enrollment Status: Completed
Publish Date: January 17, 2023
Intervention Type: Device
Study Phase: Not Applicable
View 5 Less Clinical Trials

9 Total Publications

From Trauma to Transformation: A Case Report of Interdisciplinary Rehabilitation of Fractured and Discoloured Maxillary Incisors.
From Trauma to Transformation: A Case Report of Interdisciplinary Rehabilitation of Fractured and Discoloured Maxillary Incisors.
Journal: Cureus
Published: February 17, 2025
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Nabil Adra
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Nabil Adra
Hematology Oncology | Hematology | Oncology

Iu Health Medical Group LLC

1701 N Senate Blvd, 
Indianapolis, IN 
 (54.8 miles away)
888-484-3258
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nabil Adra is a Hematologist Oncology specialist and a Hematologist in Indianapolis, Indiana. Dr. Adra is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Testicular Cancer, Teratoma of the Mediastinum, Prostate Cancer, Orchiectomy, and Bone Marrow Transplant. Dr. Adra is currently accepting new patients.

Costantine Albany
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Costantine Albany
Oncology | Hematology Oncology | Hematology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Costantine Albany
Oncology | Hematology Oncology | Hematology

Franciscan Physician Network

1701 S Creasy Ln, 1w93, 
Lafayette, IN 
 (0.1 miles away)
765-502-4015
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Costantine Albany is an Oncologist and a Hematologist Oncology provider in Lafayette, Indiana. Dr. Albany is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Testicular Cancer, Urothelial Cancer, Prostate Cancer, Orchiectomy, and Bone Marrow Transplant. Dr. Albany is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Theodore Logan
Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Theodore Logan
Hematology | Oncology

Iu Health Medical Group LLC

1701 N Senate Blvd, 
Indianapolis, IN 
 (54.8 miles away)
888-484-3258
Languages Spoken:
English
See accepted insurances

Theodore Logan is a Hematologist and an Oncologist in Indianapolis, Indiana. Dr. Logan is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Melanoma, WT1-Related Wilms Tumor Syndromes, and Chromophobe Renal Cell Carcinoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ahmed's expertise for a condition
ConditionClose
    View All 13 Distinguished Conditions
    View All 45 Advanced Conditions
    View All 119 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile